Oncolytics Biotech Inc T.ONC

Alternate Symbol(s): ONCY

Healthcare Biotechnology

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.

TSX:ONC - Post by User

Oncolytics Biotech Inc

Bullboard Posts

Comment by carduon Oct 29, 2010 10:39am

540 Views

Post# 17630054

RE: Bought deal financing

My math says that if everything is exercised it will bring in $45.523 million on almost 9 million additional shares.

- 5.44m x $4.60     = $25.042m (initial offering)
- 2.72m x $6.15     = $16.728m (warrants)
- 0.816m x $4.60   = $ 3.753m (15% over subscribed)

- 8.976m shares   = $ 45.523m (totals)

Add the above to the existing cash of around $20m and there should be enough to see us through. I doubt if a potential partner will like these figures!

Bullboard Posts

Thunder Gold makes generational discovery